Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508790 | 0.92 | BHMT (0.35) | BHMTGRM4S1PR1S1PR3LPAR3 | |
| SCHEMBL6344059 | 0.85 | GRM4 (0.35) | BHMTGRM4 | |
| SCHEMBL6354686 | 0.85 | LPAR3 (0.37) | BHMTLPAR3LPAR1LPAR2 | |
| SCHEMBL6410122 | 0.82 | S1PR1 (0.30) | BHMTS1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5974079 | 0.80 | LPAR3 (0.39) | GRM4S1PR1S1PR3LPAR3LPAR1 | |
| SCHEMBL7157667 | 0.79 | LPAR3 (0.42) | GRM4S1PR1S1PR3LPAR3LPAR1 | |
| SCHEMBL6354774 | 0.78 | BHMT (0.33) | BHMTGRM4SMPD1 | |
| SCHEMBL7158770 | 0.76 | LPAR3 (0.41) | GRM4S1PR1S1PR3LPAR3LPAR1 | |
| SCHEMBL6257990 | 0.76 | TPI1 (0.36) | GRM4S1PR1S1PR3LPAR3LPAR1 | |
| SCHEMBL6262488 | 0.74 | PGK1 (0.34) | GRM4S1PR1S1PR3LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | BHMT 353/4885GRM4 897/4885S1PR1 556/4885 |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | BHMT 396/4885GRM4 770/4885S1PR1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.